Schechter Investment Advisors LLC Increases Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Schechter Investment Advisors LLC increased its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 383.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,247 shares of the company's stock after acquiring an additional 22,401 shares during the quarter. Schechter Investment Advisors LLC's holdings in Dr. Reddy's Laboratories were worth $446,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RDY. Robeco Institutional Asset Management B.V. grew its holdings in Dr. Reddy's Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after buying an additional 9,373,412 shares during the period. Van ECK Associates Corp grew its holdings in Dr. Reddy's Laboratories by 609.4% in the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock valued at $92,000 after purchasing an additional 5,015 shares during the period. World Investment Advisors LLC acquired a new position in Dr. Reddy's Laboratories during the third quarter worth approximately $3,459,000. Allspring Global Investments Holdings LLC raised its stake in Dr. Reddy's Laboratories by 400.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock worth $8,373,000 after purchasing an additional 427,573 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its holdings in shares of Dr. Reddy's Laboratories by 328.3% in the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company's stock valued at $201,000 after purchasing an additional 9,781 shares during the last quarter. 3.85% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. StockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Nomura downgraded Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Trading Down 0.5 %

RDY stock traded down $0.06 during midday trading on Friday, reaching $12.93. 1,518,509 shares of the company's stock traded hands, compared to its average volume of 1,236,898. The business has a 50-day moving average price of $14.18 and a two-hundred day moving average price of $14.94. Dr. Reddy's Laboratories Limited has a fifty-two week low of $12.62 and a fifty-two week high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a market capitalization of $10.79 billion, a P/E ratio of 20.59 and a beta of 0.48.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.